TY - JOUR
T1 - Precision medicine in pediatric oncology
T2 - Translating genomic discoveries into optimized therapies
AU - Tran, Thai Hoa
AU - Shah, Avanthi Tayi
AU - Loh, Mignon L.
N1 - Funding Information:
This work was supported by Alex's Lemonade Stand Foundation (to T.H. Tran and M.L. Loh), Leukemia & Lymphoma Society (6466-15; to M.L. Loh), St. Baldrick's Foundation (to A.T. Shah and M.L. Loh), NIH (1P50GM115279, P50 CA196519, U01CA176063, U10CA180886; to M.L. Loh), and Frank A. Cam-pini Foundation.
Publisher Copyright:
©2017 AACR.
PY - 2017/9/15
Y1 - 2017/9/15
N2 - Survival of children with cancers has dramatically improved over the past several decades. This success has been achieved through improvement of combined modalities in treatment approaches, intensification of cytotoxic chemotherapy for those with high-risk disease, and refinement of risk stratification incorporating novel biologic markers in addition to traditional clinical and histologic features. Advances in cancer genomics have shed important mechanistic insights on disease biology and have identified "driver" genomic alterations, aberrant activation of signaling pathways, and epigenetic modifiers that can be targeted by novel agents. Thus, the recently described genomic and epigenetic landscapes of many childhood cancers have expanded the paradigm of precision medicine in the hopes of improving outcomes while minimizing toxicities. In this review, we will discuss the biologic rationale for molecularly targeted therapies in genomically defined subsets of pediatric leukemias, solid tumors, and brain tumors.
AB - Survival of children with cancers has dramatically improved over the past several decades. This success has been achieved through improvement of combined modalities in treatment approaches, intensification of cytotoxic chemotherapy for those with high-risk disease, and refinement of risk stratification incorporating novel biologic markers in addition to traditional clinical and histologic features. Advances in cancer genomics have shed important mechanistic insights on disease biology and have identified "driver" genomic alterations, aberrant activation of signaling pathways, and epigenetic modifiers that can be targeted by novel agents. Thus, the recently described genomic and epigenetic landscapes of many childhood cancers have expanded the paradigm of precision medicine in the hopes of improving outcomes while minimizing toxicities. In this review, we will discuss the biologic rationale for molecularly targeted therapies in genomically defined subsets of pediatric leukemias, solid tumors, and brain tumors.
UR - http://www.scopus.com/inward/record.url?scp=85029523286&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85029523286&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-16-0115
DO - 10.1158/1078-0432.CCR-16-0115
M3 - Review article
C2 - 28600472
AN - SCOPUS:85029523286
SN - 1078-0432
VL - 23
SP - 5329
EP - 5338
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 18
ER -